Opin vísindi

Fletta eftir höfundi "Jóhannsson, Óskar Þór"

Fletta eftir höfundi "Jóhannsson, Óskar Þór"

Röðun: Raða: Niðurstöður:

  • Icon
    Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study. 
    Jakubowska, A; Rozkrut, D; Antoniou, A; Hamann, U; Scott, R J; McGuffog, L; Healy, S; Sinilnikova, O M; Rennert, G; Lejbkowicz, F; Flugelman, A; Andrulis, I L; Glendon, G; Ozcelik, H; Thomassen, M; Paligo, M; Aretini, P; Kantala, J; Aroer, B; von Wachenfeldt, A; Liljegren, A; Loman, N; Herbst, K; Kristoffersson, U; Rosenquist, R; Karlsson, P; Stenmark-Askmalm, M; Melin, B; Nathanson, K L; Domchek, S M; Byrski, T; Huzarski, T; Gronwald, J; Menkiszak, J; Cybulski, C; Serrano, P; Osorio, A; Cajal, T R; Tsitlaidou, M; Benítez, J; Gilbert, M; Rookus, M; Aalfs, C M; Kluijt, I; Boessenkool-Pape, J L; Meijers-Heijboer, H E J; Oosterwijk, J C; van Asperen, C J; Blok, M J; Nelen, M R; van den Ouweland, A M W; Seynaeve, C; van der Luijt, R B; Devilee, P; Easton, D F; Peock, S; Frost, D; Platte, R; Ellis, S D; Fineberg, E; Evans, D G; Lalloo, F; Eeles, R; Jacobs, C; Adlard, J; Davidson, R; Eccles, D; Cole, T; Cook, J; Godwin, A; Bove, B; Stoppa-Lyonnet, D; Caux-Moncoutier, V; Belotti, M; Tirapo, C; Mazoyer, S; Barjhoux, L; Boutry-Kryza, N; Pujol, P; Coupier, I; Peyrat, J-P; Vennin, P; Muller, D; Fricker, J-P; Venat-Bouvet, L; Jóhannsson, Óskar Þór; Isaacs, C; Schmutzler, R; Wappenschmidt, B; Meindl, A; Arnold, N; Varon-Mateeva, R; Niederacher, D; Sutter, C; Deissler, H; Preisler-Adams, S; Simard, J; Soucy, P; Durocher, F; Chenevix-Trench, G; Beesley, J; Chen, X; Rebbeck, T; Couch, F; Wang, X; Lindor, N; Fredericksen, Z; Pankratz, V S; Peterlongo, P; Bonanni, B; Fortuzzi, S; Peissel, B; Szabo, C; Mai, P L; Loud, J T; Lubinski, J (2012-06-05)
    The variable penetrance of breast cancer in BRCA1/2 mutation carriers suggests that other genetic or environmental factors modify breast cancer risk. Two genes of special interest are prohibitin (PHB) and methylene-tetrahydrofolate reductase (MTHFR), ...
  • Icon
    The BRCA1 c.4096+3A>G Variant Displays Classical Characteristics of Pathogenic BRCA1 Mutations in Hereditary Breast and Ovarian Cancers, But Still Allows Homozygous Viability 
    Arason, Adalgeir; Agnarsson, Bjarni A.; Jóhannesdóttir, Gudrún; Jóhannsson, Óskar Þór; Hilmarsdóttir, Bylgja; Reynisdóttir, Inga; Barkardottir, Rosa Bjork (MDPI AG, 2019-11-01)
    Mutations in BRCA1 result in predisposal to breast and ovarian cancers, but many variants exist with unknown clinical significance (VUS). One is BRCA1 c.4096+3A>G, which affects production of the full-length BRCA1 transcript, while augmenting transcripts ...
  • Icon
    Brca1 promoter methylation status in 1031 primary breast cancers predicts favorable outcomes following chemotherapy 
    Stefánsson, Ólafur A.; Hilmarsdóttir, Hólmfridur; Ólafsdóttir, Kristrún; Tryggvadóttir, Laufey; Sverrisdóttir, Ásgerdur; Jóhannsson, Óskar Þór; Jónasson, Jón Gunnlaugur; Eyfjörð, Jórunn Erla; Sigurdsson, Stefán Þórarinn (2019-12-11)
    Background: Breast Cancer 1 gene (BRCA1) is known to be inactivated in breast tumors by promoter methylation. Tumor cells in patients carrying a germline mutation in BRCA1 are sensitive to cytotoxic drugs that cause DNA double strand breaks. However, ...
  • Icon
    A Breast Cancer Candidate Locus at 6q Narrowed to 6q15-q21 
    Csuka, Dorottya; Freysteinsdóttir, Edda Sigríður; Jóhannesdóttir, Guðrún; Agnarsson, Bjarni Agnar; Jóhannsson, Óskar Þór; Barkardóttir, Rósa Björk; Arason, Aðalgeir (2024-02-08)
    Although a number of high-risk breast cancer genes have been identified, including BRCA1 and BRCA2, the risk profile of many high-risk families cannot be explained using known breast cancer genes. Previously, we have shown strong indications of new ...
  • Icon
    Correction : Polygenic risk modeling for prediction of epithelial ovarian cancer risk 
    GEMO Study Collaborators; Jóhannsson, Óskar Þór (2022-05)
  • Icon
    High Atlastin 2-2 (ATL2-2) Expression Associates with Worse Prognosis in Estrogen-Receptor-Positive Breast Cancer 
    Reynisdóttir, Inga; Arason, Aðalgeir; Freysteinsdóttir, Edda Sigríður; Kristjánsdóttir, Sigrún Bærings; Hilmarsdóttir, Bylgja; Traustadóttir, Gunnhildur Ásta; Jóhannsson, Óskar Þór; Agnarsson, Bjarni Agnar; Barkardóttir, Rósa Björk (2023-08)
    The disruption of endoplasmic reticulum (ER) homeostasis occurs in many human diseases. Atlastins (ATLs) maintain the branched network of the ER. The dysregulation of ATL2, located at ER network junctions, has been associated with cancer. ATL2 is ...
  • Icon
    High expression of the vacuole membrane protein 1 (VMP1) is a potential marker of poor prognosis in HER2 positive breast cancer 
    Amirfallah, Arsalan; Arason, Adalgeir; Einarsson, Hjörleifur; Guðmundsdóttir, Eydís Þórunn; Freysteinsdóttir, Edda Sigríður; Ólafsdóttir, Kristrún Auður; Jóhannsson, Óskar Þór; Agnarsson, Bjarni A.; Barkardottir, Rosa Bjork; Reynisdottir, Inga (Public Library of Science (PLoS), 2019-08-23)
    Background: Fusion genes result from genomic structural changes, which can lead to alterations in gene expression that supports tumor development. The aim of the study was to use fusion genes as a tool to identify new breast cancer (BC) genes with a ...
  • Icon
    Hsa-miR-21-3p associates with breast cancer patient survival and targets genes in tumor suppressive pathways 
    Amirfallah, Arsalan; Knutsdottir, Hildur; Arason, Aðalgeir; Hilmarsdóttir, Bylgja; Jóhannsson, Óskar Þór; Agnarsson, Bjarni Agnar; Barkardottir, Rosa B.; Reynisdottir, Inga (2021-11-19)
    Breast cancer is the cancer most often diagnosed in women. MicroRNAs (MIRs) are short RNA molecules that bind mRNA resulting in their downregulation. MIR21 has been shown to be an oncomiR in most cancer types, including breast cancer. Most of the effects ...
  • Icon
    Polygenic risk modeling for prediction of epithelial ovarian cancer risk 
    GEMO Study Collaborators; Barkardóttir, Rósa Björk; Jóhannsson, Óskar Þór (2022-01-14)
    Polygenic risk scores (PRS) for epithelial ovarian cancer (EOC) have the potential to improve risk stratification. Joint estimation of Single Nucleotide Polymorphism (SNP) effects in models could improve predictive performance over standard approaches ...